Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T Rapidly building our portfolio in Immunology LPA₁ Antagonist: New potential standard of care in IPF & PPF with registrational Phase 3 programs initiating Sotyktu: Compelling Phase 2 data supports ongoing registrational Phase 3 programs in SLE & SjS CD19 NEX T: Phase 1 study in severe, refractory SLE initiated and expanding into other immunologic diseases Exciting additional registrational Phase 3 programs: Cendakimab in EoE & EGE Zeposia in CD Sotyktu in PSA Exploring 5 additional assets in early development across indications Addressing immunologic diseases with high unmet need impacting 8M+1 patients Ill Bristol Myers Squibb™ 1. 2023 estimates from Decision Resource Group & BMS Internal Analysis across indications in the U.S. & EU5 Not for Product Promotional Use 72

View entire presentation